Managed care's perspective on treatment of plaque psoriasis.

Sullivan discussed the potential for acceptance of biologic drugs for treatment of psoriasis in the context of how managed care organizations currently respond to new therapies. The apparent effectiveness of biologic therapies, compared with conventional treatments, led Sullivan to suggest that traditional methods of evaluating and "tiering" pharmaceutical products may not necessarily prove appropriate for biologic therapies.